Acarbose

Subscribe to Selected New Research on Acarbose

437 relevant articles (84 outcomes, 121 trials/studies) found for this Drug

Description: An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)

Also Known As:

Bay g 5421; Bayer Brand of Acarbose; Glucobay; Glucor; Glumida; Lasa Brand of Acarbose; Prandase; Precose; D-glucose, O-4,6-dideoxy-4-(((1S-(1 alpha,4 alpha,5 beta,6 alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyr anosyl-(1-4)-

Relationship Network

Drug Context: Research Results

Carbohydrates: 2945

Polysaccharides: 1669

Oligosaccharides: 1072

Trisaccharides: 23

Acarbose: 437

component C acarbose byproduct

Experts

1.	Hanefeld, Markolf: 5 articles (06/2008 - 06/2002)
2.	Chiasson, Jean-Louis: 5 articles (01/2006 - 06/2002)
3.	Petzinna, Dieter: 3 articles (01/2005 - 10/2004)
4.	STOP-NIDDM Trial Research Group: 3 articles (10/2004 - 07/2003)
5.	Laakso, Markku: 3 articles (07/2003 - 06/2002)
6.	Landen, Harald: 2 articles (01/2007 - 01/2006)
7.	Bali, Deeksha: 2 articles (05/2006 - 05/2006)
8.	Kishnani, Priya S: 2 articles (05/2006 - 05/2006)
9.	Spengler, M: 2 articles (01/2005 - 01/2000)
10.	Yamagishi, S: 2 articles (01/2005 - 01/2005)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2005 - "The STOP-NIDDM trial confirmed the efficacy of acarbose in decreasing the risk of diabetes by 36% in similar high risk population. " 01/01/2006 - "CONCLUSION: The STOP-NIDDM Trial demonstrated that, in subjects with IGT, acarbose treatment was effective in reducing the risk of type 2 diabetes. " 02/16/1997 - "Acarbose was shown to be effective in treating NIDDM and to be safe and well-tolerated." 03/01/1989 - "These findings demonstrate that acarbose is effective in moderating the metabolic effects of NIDDM in this diabetic rodent model, and suggest that acarbose may have potential in the management of NIDDM in humans." 02/01/1996 - "These results indicate that treatment with acarbose is safe and effective in adjunct to dietary therapy for the treatment of NIDDM." Order ALL the reference details at left...
2.	Hyperglycemia 11/01/1996 - "DATA SYNTHESIS: Acarbose is effective in reducing postprandial hyperglycemia. " 11/01/2009 - "Acarbose has been shown to have a beneficial effect on postprandial hyperglycemia in diabetic patients. " 01/01/2007 - "Action of acarbose is based on local inhibition of intestinal enzyme alpha-glycosidase, what leads to diminishment of postprandial hyperglycemia peak. " 09/01/2006 - "Treatment with acarbose is helpful to prevent the increase in oxidative stress and vascular dysfunction induced by hyperglycemia." 09/01/2006 - "However, there was no difference in the cumulative rate of frank fasting hyperglycemia (29% with acarbose and 34% with placebo; P = 0.65 for survival analysis). " Order ALL the reference details at left...
3.	Diabetes Mellitus 01/01/1999 - "Acarbose observational study performed in the routine treatment conditions confirmed efficacy of the drug in diabetes mellitus, for both--carbohydrate and lipid metabolism. " 09/01/1998 - "Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials." 09/01/1996 - "A review of the safety and efficacy of acarbose in diabetes mellitus." 01/01/2005 - "OBJECTIVE: The efficacy and tolerability of acarbose were examined in a postmarketing surveillance study of 27 803 patients with diabetes mellitus (26 044 were diagnosed as having type 2 diabetes) over a 12-week treatment period. " 01/01/2005 - "Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study." Order ALL the reference details at left...
4.	Body Weight (Weight, Body) 01/01/2005 - "In this analysis, glycemic control, triglyceride levels, body weight and systolic blood pressure was also significantly improved during acarbose treatment. " 01/01/2004 - "Glycaemic control, triglyceride levels, body weight and systolic blood pressure also improved significantly during acarbose treatment. " 09/01/2003 - "Loss of body weight was also significantly greater for acarbose than placebo subjects. " 03/01/1997 - "The PROTECT study confirms the previously demonstrated efficacy and safety of acarbose in improving glycemic control in patients with type II diabetes regardless of a patient's age, body weight, ethnic background, time since diagnosis, or severity of disease. " 11/01/1995 - "Body weight also decreased significantly (P < 0.001) at the end of acarbose trial. " Order ALL the reference details at left...
5.	Insulin Resistance 02/01/2009 - "Further, recently, acarbose has been shown to improve insulin resistance in vivo. " 04/01/2006 - "In addition, acarbose treatment prevented the deterioration in insulin resistance with increasing age. " 01/01/2005 - "Given the pathological link between NASH and insulin resistance, we would like to hypothesize here that acarbose may become a promising therapeutic strategy for the treatment of patients with NASH. " 09/01/2004 - "Improvement of insulin resistance with acarbose may also reduce fasting TG levels in DM2 with hypertriglyceridaemia. " 01/01/2004 - "RESULTS: Insulin resistance decreased in acarbose users but not on placebo. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	alpha-Glucosidases (Acid Maltase)
2.	Glucose (Dextrose)
3.	Metformin (Glucophage)
4.	Insulin (Novolin)
5.	Acarbose
6.	Blood Glucose (Blood Sugar)
7.	Hypoglycemic Agents (Hypoglycemics)
8.	Lipoproteins (Lipoprotein)
9.	Glyburide (Glibenclamide)
10.	Glucosidases

Related Therapies and Procedures

1.	Long-Term Care
2.	Drug Therapy (Chemotherapy)
3.	Fundoplication
4.	Exercise Therapy (Therapy, Exercise)
5.	Carbohydrate-Restricted Diet (Low Carbohydrate Diet)

Best Treatments:
Research Summary Report
on Type 2 Diabetes Mellitus

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 666 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>